Mitochondrial Malfunctioning, Proteasome Arrest and Apoptosis in Cancer Cells by Focused Intracellular Generation of Oxygen Radicals

International Journal of Molecular Sciences
I PostiglioneGiovanna Maria Pierantoni

Abstract

Photofrin/photodynamic therapy (PDT) at sub-lethal doses induced a transient stall in proteasome activity in surviving A549 (p53(+/+)) and H1299 (p53(-/-)) cells as indicated by the time-dependent decline/recovery of chymotrypsin-like activity. Indeed, within 3 h of incubation, Photofrin invaded the cytoplasm and localized preferentially within the mitochondria. Its light activation determined a decrease in mitochondrial membrane potential and a reversible arrest in proteasomal activity. A similar result is obtained by treating cells with Antimycin and Rotenone, indicating, as a common denominator of this effect, the ATP decrease. Both inhibitors, however, were more toxic to cells as the recovery of proteasomal activity was incomplete. We evaluated whether combining PDT (which is a treatment for killing tumor cells, per se, and inducing proteasome arrest in the surviving ones) with Bortezomib doses capable of sustaining the stall would protract the arrest with sufficient time to induce apoptosis in remaining cells. The evaluation of the mitochondrial membrane depolarization, residual proteasome and mitochondrial enzymatic activities, colony-forming capabilities, and changes in protein expression profiles in A549 and H1299 cells...Continue Reading

References

Oct 15, 1992·Biochemical and Biophysical Research Communications·J J MaguireL Packer
Jun 24, 1998·Journal of the National Cancer Institute·T J DoughertyQ Peng
May 29, 1999·The Journal of Biological Chemistry·A Barrientos, C T Moraes
Apr 24, 2001·International Journal of Radiation Oncology, Biology, Physics·S M RussoJ C Cusack
Mar 28, 2002·Physiological Reviews·Michael H Glickman, Aaron Ciechanover
May 11, 2002·Nature Reviews. Cancer·Michael KarinZhi-Wei Li
May 2, 2003·Nature Reviews. Cancer·Dennis E J G J DolmansRakesh K Jain
Sep 26, 2003·American Journal of Clinical Dermatology·Aditya K Gupta, Jennifer E Ryder
May 4, 2004·Nature Reviews. Cancer·Julian Adams
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christos N PapandreouChristopher J Logothetis
Jun 3, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xin-Yan PeiSteven Grant
Sep 15, 2004·Biochimica Et Biophysica Acta·Ramiro D AlmeidaCarlos B Duarte
Jan 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vincent RajkumarKenneth C Anderson
Jan 24, 2006·Critical Reviews in Oncology/hematology·Giorgio Scagliotti
Aug 2, 2006·The Journal of Biological Chemistry·Priyanka DikshitNihar Ranjan Jana
Mar 6, 2007·Expert Opinion on Drug Delivery·Giuseppe Palumbo
Aug 8, 2009·Annual Review of Genetics·Chunxin Wang, Richard J Youle

❮ Previous
Next ❯

Methods Mentioned

BETA
confocal microscopy
protein profiling
xenograft
FCS
ELISA

Software Mentioned

Summit

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis